3 results about "In vitro growth" patented technology

Embodiments described herein relate generally to devices, apparatuses, and systems with embedded electrodes for growing, maintaining, and / or using 3D tissues in vitro. The devices, apparatuses, and systems described herein can provide scalable, automated tissue stimulation.

The application discloses tumor-related fibroblasts which can be targeted to die, the tumor-related fibroblasts carry polynucleotide fragments of sequences such as SEQ ID No:1 in chromosomes, and the tumor-related fibroblasts have morphology and in-vitro growth rate comparable to other tumor-related fibroblasts.The tumor-related fibroblasts can be specifically induced to die by drugs when co-cultured with other tumor-related fibroblasts, and the drugs are ganciclovir, and the ganciclovir drug concentration ranges from 1 to 100 μM.The application provides a novel and convenient cell construction method for studying the functions of different subtypes of CAFs and application thereof, and the novel CAFs can be targeted to die under the treatment of ganciclovir, weaken the effect of the CAFs of the type on co-cultured tumor cells, and help effectively distinguish the roles of different subtypes of CAFs in tumor occurrence and development.

The application discloses a Cryptosporidium parvum CpDHR1 gene replacement strain and a construction method and application thereof. The application researches and finds that the CpDHR1 gene of Cryptosporidium parvum is related to virulence, the CpDHR1 gene of a high-virulence strain is replaced by the CpDHR1 gene of a low-virulence strain through a gene editing technology, and a Cryptosporidium parvum CpDHR1 gene replacement strain is successfully constructed. Research shows that after the CpDHR1 gene of a high-virulence wild-type Cryptosporidium parvum IIdA20G1 subtype strain is replaced, the strain can still be cultured in vitro, but the in-vitro growth of the strain is significantly reduced, the virulence of the strain is weakened, the oocyst excretion intensity of the strain is weakened, the oocyst load in mice is reduced, the clinical symptoms of the mice are alleviated, the survival time of the mice is prolonged, the virulence of the strain is significantly weakened, the strain can be used for preparing a Cryptosporidium parvum low-virulence vaccine product, and Cryptosporidium parvum infection can be better prevented.